Silvia Del Ry, Daniela Giannessi, Aldo Clerico
Plasma Brain Natriuretic Peptide Measured by Fully-Automated Immunoassay and by Immunoradiometric Assay Compared
The clinical relevance of measuring plasma brain natriuretic
peptide (BNP) is well-known, especially in patients
with heart failure. Recently, a new method for
measuring BNP, called TRIAGE®, has been developed
which can be used for point-of-care testing of patients
with congestive heart failure. The aim of the present
study is to compare the analytical performance of this
fully-automated method to that of an immunoradiometric
assay (IRMA), routinely used to measure BNP.
The TRIAGE® method is a non-competitive immunofluorometric
assay which uses two different binding
phases, specific for two different epitopes of the BNP
amino acid chain, to form a sandwich with the specific
ligand (i.e., BNP). A polyclonal antibody is included in
the fluorescent immunoassay reagents which are contained
in the assay devices and a monoclonal antibody
is immobilized in the detection lane of the assay device.
The imprecision of the TRIAGE® method was approximately
12% for BNP concentrations in the normal
range and about 18% for BNP concentrations above
the normal range. The mean reading time of the
TRIAGE® method was 14.5±8.6 min. A close linear relationship
was found between the BNP values measured
with the two methods (TRIAGE=24.6+0.933 IRMA;
r=0.932, n=83). The TRIAGE® method is indicated for
BNP assay in ambulatory and coronary or emergency
units, where usually only a few samples (preferentially
whole blood samples) must be measured in a short
time. The IRMA method should be preferred for pathophysiological
studies, requiring the highest degree of
precision and sensitivity for simultaneous measurement
of several stored plasma samples or tissue extracts.
Clinical Chemical Laboratory Medicine, Walter de Gruyter
Print ISSN: 1434-6621
Volume: 39, 06/2001
Pages: 446 - 450
Show full article (external site)
Show all available items of this journal